GlassScriptPhysician profile
Diana Castanon Westgate
NPI 1265648299
$252,481.57
in general payments reported to CMS, 2019-2025
40 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $12K · 2021: $11K · 2022: $22K · 2023: $58K · 2024: $27K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $15K · Honoraria: $14K · Food and Beverage: $11K · Consulting Fee: $2,258 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,862.50 |
| Travel and Lodging | $15,454.54 |
| Honoraria | $13,800.00 |
| Food and Beverage | $10,587.26 |
| Consulting Fee | $2,257.50 |
| Education | $298.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222,396.63 | 2019-2025 | Skyrizi, Rinvoq |
| Organon LLC | $15,775.35 | 2023-2025 | Vtama, Hadlima, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $2,697.15 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $2,148.51 | 2020-2025 | Tremfya, Stelara, Remicade |
| Sun Pharmaceutical Industries INC. | $1,200.79 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Incyte Corporation | $1,077.40 | 2021-2025 | Opzelura |
| Genzyme Corporation | $1,013.25 | 2019-2025 | |
| Ucb, INC. | $719.46 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $718.24 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $601.30 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $544.65 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $523.51 | 2020-2025 | |
| Galderma Laboratories, L.P. | $480.81 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $450.00 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $400.48 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Westgate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.